Kura Oncology, Inc. (KURA) by event type
KURA moves most on coverage initiations — a median of -1.43% at 30 minutes across 14 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the KURA overview →
How KURA reacts across 5 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 2,336 of 2,717 | 15 | -0.43% | 47% | -0.69% |
| Analyst downgrades 2,105 of 2,603 | 14 | -0.39% | 36% | +0.54% |
| Coverage initiations 2,172 of 2,283 | 14 | -1.43% | 43% | -0.01% |
| Rating reiterations 2,987 of 3,522 | 114 | -0.23% | 40% | -0.39% |
| Price-target cuts 62 of 1,527 | 11 | +0.44% | 64% | +1.01% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 1 further class was observed with fewer than 10 measured events and is not published.
That’s how KURA usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Coverage initiations → · Rating reiterations → · Price-target cuts → · KURA overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
| Penumbra, Inc. (PEN) | 369 | +0.06% | 60% |
| Arcus Biosciences, Inc. (RCUS) | 368 | -0.09% | 45% |
| Ligand Pharmaceuticals Incorporated (LGND) | 367 | +0.06% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.